Small molecules bind human mTOR protein and inhibit mTORC1 specifically

Albert, 2015, mTOR signaling in cellular and organismal energetics, Curr. Opin. Cell Biol., 33, 55, 10.1016/j.ceb.2014.12.001 Vezina, 1975, Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle, J. Antibiotics, 28, 721, 10.7164/antibiotics.28.721 Oka, 1996, Immunosuppression in organ transplantation, Jpn. J. Pharmacol., 71, 89, 10.1254/jjp.71.89 Dancey, 2006, Therapeutic targets: MTOR and related pathways, Cancer Biol. Therapy, 5, 1065, 10.4161/cbt.5.9.3175 Johnson, 2013, mTOR inhibition alleviates mitochondrial disease in a mouse model of Leigh syndrome, Science, 342, 1524, 10.1126/science.1244360 Sharma, 2010, Dysregulation of mTOR signaling in fragile X syndrome, J. Neurosci., 30, 694, 10.1523/JNEUROSCI.3696-09.2010 Laplante, 2012, mTOR signaling in growth control and disease, Cell, 149, 274, 10.1016/j.cell.2012.03.017 Phan, 2016, The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumors, Cancer Med., 5, 2953, 10.1002/cam4.742 Chow, 2016, A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer, Cancer, 122, 1897, 10.1002/cncr.29927 Xie, 2016, mTOR inhibitors in cancer therapy, F1000Research, 5 Linke, 2017, mTORC1 and mTORC2 as regulators of cell metabolism in immunity, FEBS Lett., 591, 3089, 10.1002/1873-3468.12711 Dibble, 2013, Signal integration by mTORC1 coordinates nutrient input with biosynthetic output, Nature Cell Biol., 15, 555, 10.1038/ncb2763 Nojima, 2003, The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif, J. Biol. Chem., 278, 15461, 10.1074/jbc.C200665200 Sparks, 2010, Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy, Oncogene, 29, 3733, 10.1038/onc.2010.139 Sarbassov, 2005, Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex, Science, 307, 1098, 10.1126/science.1106148 Meng, 2015, Toward rapamycin analog (rapalog)-based precision cancer therapy, Acta Pharmacol. Sinica, 36, 1163, 10.1038/aps.2015.68 Vicary, 2016, Targeting the mammalian target of rapamycin in lung cancer, Am. J. Med. Sci., 352, 507, 10.1016/j.amjms.2016.08.014 Schenone, 2011, ATP-competitive inhibitors of mTOR: an update, Curr. Med. Chem., 18, 2995, 10.2174/092986711796391651 C. Di Malta, D. Siciliano, A. Calcagni, J. Monfregola, S. Punzi, Transcriptional activation of RagD GTPase controls mTORC1 and promotes cancer growth, 2017, 356(6343), 1188–1192. Chen, 2014, Hyperactivation of mammalian target of rapamycin complex 1 (mTORC1) promotes breast cancer progression through enhancing glucose starvation-induced autophagy and Akt signaling, J. Biol. Chem., 289, 1164, 10.1074/jbc.M113.526335 Morisot, 2017, A new generation of mTORC1 inhibitor attenuates alcohol intake and reward in mice, Addict. Biol. Fan, 2017, A kinase inhibitor targeted to mTORC1 drives regression in glioblastoma, Cancer Cell, 31, 424, 10.1016/j.ccell.2017.01.014 Feng, 2005, The coordinate regulation of the p53 and mTOR pathways in cells, Proc. Natl. Acad. Sci. U.S.A., 102, 8204, 10.1073/pnas.0502857102 Chen, 1995, Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue, Proc. Natl. Acad. Sci. U.S.A., 92, 4947, 10.1073/pnas.92.11.4947 Wan, 2007, Rapamycin induces feedback activation of Akt signaling through and IGF-1R-dependent mechanism, Oncogene, 26, 1932, 10.1038/sj.onc.1209990 Schmeel, 2015, In vitro efficacy of cinnarizine against lymphoma and multiple myeloma, Anticancer Res., 35, 835 Bellelli, 1987, In vitro and in vivo enhancement of vincristine antitumor activity on B16 melanoma cells by calcium antagonist flunarizine, Oncology, 44, 17, 10.1159/000226436 Castellino, 1995, Flunarizine enhancement of melphalan activity against drug-sensitive/resistant rhabdomyosarcoma, Br. J. Cancer, 71, 1181, 10.1038/bjc.1995.230 Wood, 1988, Cinnarizine and flunarizine as radiation sensitisers in two murine tumours, Br. J. Cancer, 58, 742, 10.1038/bjc.1988.301 Fasolo, 2008, mTOR inhibitors in the treatment of cancer, Expert Opin. Investig. Drugs, 17, 1717, 10.1517/13543784.17.11.1717 Schmeel, 2015, Flunarizine exhibits in vitro efficacy against lymphoma and multiple myeloma cells, Anticancer Res., 35, 1369